The European Prevention of Alzheimer's Dementia (EPAD) project was an Innovative Medicines Initiative (IMI)-program aiming to facilitate secondary prevention of Alzheimer’s disease dementia research. The project recruited over 2,000 research participants into the EPAD longitudinal cohort study (LCS) and included over 400 researchers from 39 partners. In a recent article published in a Special Issue of the Frontiers in Neurology journal, the EPAD Consortium summarised the key findings of the EPAD study to date, detailed the data access policy and discussed the substantial assets of the EPAD project for the scientific community, patient population and industry. Additionally, authors described the EPAD structure with a focus on how the public and private sector interacted and collaborated within the project, reflected how IMI specifically supported the achievements of the project, and concluded with a view for future. Authors include Stina Saunders, Sarah Gregory, Matthew Clement, AE Project Officer Cindy Birck, Serge van der Geyten and Craig Ritchie. The EPAD project received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement no 115736 and an Alzheimer's Association Grant (SG-21-8180990-EPAD). Read the full article, here: https://doi.org/10.3389/fneur.2022.1051543